Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s): MDNAF

Healthcare Biotechnology

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

TSX:MDNA - Post by User

Medicenna Therapeutics Corp

<< Previous

Bullboard Posts

Next >>

Post by Sunvalleyon Dec 28, 2020 12:34pm

229 Views

Post# 32187666

Goint up.

mdna is up $1.03 US on the nazdaq in the states today. Bodes well for the Canadian open in the morning if the price holds up. In my opinion we will eventially see $20.00 to $30.00 price in this stock , as it,s Cancer drug is becoming better known to investors.Do your own DD and have a look at the potential before you invest.

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports